3 days popular7 days popular1 month popular3 months popular

UK’s NICE issues positive final guidance for Selincro

Therapies () announces that the National Institute for Health and Care Excellence (NICE), the United Kingdom’s authority, has issued its final guidance for Selincro (nalmefene), recommending its use within the conditions of its in the (NHS) in England and Wales as an option for reducing for people with . Upon issuance of the final guidance, the NHS has three months to implement the recommendation and make the necessary funding available. It is expected that up to 600,000 alcohol dependent individuals in England and Wales may be eligible for the treatment.

Selincro (nalmefene) is a dual-acting opioid system modulator and the first therapy approved in Europe for the reduction of alcohol consumption in alcohol dependent individuals. Biotie has licensed global rights to Selincro to H.Lundbeck A/S (Lundbeck). Lundbeck received European marketing authorization for Selincro in February 2013 and has to date introduced the product in well over 20 European markets.

Timo Veromaa, President and CEO of Biotie commented, “We are pleased that Selincro will now be available through the NHS to appropriate alcohol dependent patients in England and Wales. Positive reimbursement decisions have also been granted in a number of additional EU countries, including France and Spain, and our partner Lundbeck is continuing with its negotiations in order to provide access to this exciting new treatment option for patients.”


Source: Biotie